|
Jul 25
|
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Jul 25
|
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion
|
|
Jul 24
|
Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for
|
|
Jul 21
|
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
|
|
Jul 18
|
Fabry Disease Treatment Analysis Report 2025 | Market to Reach $3.86 Billion by 2030, Rising Fabry Disease Prevalence and Demand for Targeted Therapies Drive Growth
|
|
Jul 17
|
Starbucks downgraded, Oracle initiated: Wall Street's top analyst calls
|
|
Jul 16
|
Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda
|
|
Jul 12
|
TD Cowen Remains Bullish on Amicus Therapeutics (FOLD) With a $20 PT
|
|
Jul 4
|
High Growth Tech Stocks In The US To Watch This July 2025
|
|
Jun 25
|
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
|
|
Jun 24
|
Amicus Therapeutics Publishes Positive PROPEL Study Data for Pompe Disease Treatment
|
|
May 21
|
3 High Growth Tech Stocks In The US Market
|
|
May 4
|
Amicus Therapeutics First Quarter 2025 Earnings: Misses Expectations
|
|
May 2
|
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
|
|
May 1
|
Dimerix and Amicus to commercialise DMX-200 in US
|
|
May 1
|
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates
|
|
May 1
|
Amicus Therapeutics: Q1 Earnings Snapshot
|
|
May 1
|
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
|
|
Apr 30
|
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
|
|
Apr 29
|
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
|